PDS Biotechnology Corporation Gains 39.2%

PDS Biotechnology Corporation (PDSB:NASDAQ) soared at $4.19, representing a gain of 39.2%. On Fri 17 Jul 20, PDSB:NASDAQ hit a New 2-Week High of $3.01. The stock appeared on our News Catalysts scanner on Tue 14 Jul 20 at 08:48 AM in the 'PATNERSHIP' category. From Mon 06 Jul 20, the stock recorded 66.67% Up Days and 70.00% Green Days

About PDS Biotechnology Corporation (PDSB:NASDAQ)

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.